Page 1

Boston Scientific Boston Scientific Announces Results For Third Quarter 2021 MARLBOROUGH , Mass . , Oct. 27 , 2021 / PRNewswire / -- Boston Scientific Corporation ( NYSE : BSX ) generated net sales of $ 2.932 billion during the third quarter of 2021 , growing 10.3 percent on a reported basis , 9.7 percent on an operational¹ basis and 10.6 percent on an organic² basis , all compared to the prior year period . The company reported GAAP net income available to common stockholders o $ 405 million or $ 0.28 per share ( EPS ) , compared to a GAAP net loss available to common shareholders o $ 169 million or $ ( 0.12 ) per share a year ago , and achieved adjusted EPS of $ 0.41 for the period , compared to $ 0.37 a year ago . " We've seen this year that our strategy of category leadership , focus on high - growth markets and smart tuck - in M & A deals , combined with execution by our global team and an exciting pipeline , positions us well for the long term , " said Mike Mahoney , chairman and chief executive officer , Boston Scientific . " Despite some softness this quarter , including the ongoing impact of the COVID - 19 pandemic , we're confident that we will achieve our growth goals as the pandemic wanes . " Third quarter financial results and recent developments : ⚫ Reported net sales of $ 2.932 billion , representing an increase of 10.3 percent on a reported basis and 10.6 percent on an organic basis , both compared to the company's guidance range of 12 to 14 percent , all versus the prior year period . • Reported GAAP net income available to common stockholders of $ 0.28 per share , compared to the company's guidance range of $ 0.20 to $ 0.22 per share and achieved adjusted EPS of $ 0.41 compared to the guidance range of $ 0.39 to $ 0.41 per share . • Achieved net sales growth in each reportable segment , compared to the prior year period : ⚫ MedSurg : 11.2 percent reported , 10.6 percent operational and 9.4 percent organic ⚫ Rhythm and Neuro : 8.2 percent reported , 7.8 percent operational and 1.5 percent organic ⚫ Cardiovascular : 19.4 percent reported , 18.5 percent operational and organic • Achieved the following regional net sales growth , compared to the prior year period : ⚫ U.S .: 15.4 percent reported and operational ⚫ EMEA ( Europe , Middle East and Africa ) : 9.3 percent reported and 7.9 percent operational 。 APAC ( Asia - Pacific ) : 9.5 percent reported and 8.2 percent operational ° Emerging Markets³ : 21.9 percent reported and 17.8 percent operational • Completed acquisitions of the global surgical business of Lumenis LTD . , a privately held company that develops and commercializes energy - based medical solutions , and ofFarapulse , Inc. , the first company to commercialize a cardiac pulsed field ablation technology . • Announced agreements to acquire Baylis Medical Company Inc. to expand Boston Scientific electrophysiology and structural heart product portfolios , and Devoro Medical Inc. , to expand the company's full suite of interventional strategies for thromboemboli . Both acquisitions are subject to customary closing conditions . • Received U.S. Food & Drug Administration ( FDA ) clearance for the EXALT ™ Model B Single - Use Bronchoscope for use in a wide range of bronchoscopy procedures in the intensive care unit ( ICU ) and operating room ( OR ) , such as secretion management , airway intubation , percutaneous tracheostomy , double lumen endotracheal tube placement and biopsies . In the United States , more than 1.2 million bedside procedures involving a bronchoscope are performed in ICU and OR settings each year . • Received a New Technology Add - on Payment ( NTAP ) designation from the U.S. Centers for Medicare and Medicaid Services ( CMS ) for the EXALT ™ Model D Single - Use Duodenoscope used to diagnose and treat pancreatic and biliary conditions during endoscopic retrograde cholangiopancreatography ( ERCP ) procedures . • Initiated the SABRE randomized controlled trial , the first global study to examine the effectiveness oSpaceOAR Vue ™ Hydrogel in reducing late gastrointestinal toxicity in patients receiving stereotactic body radiotherapy ( SBRT ) treatment for prostate cancer . • Initiated the HI - PEITHO randomized trial , the first ever comparative study in the interventional field of PE treatment , evaluating the EkoSonic ™ Endovascular System ( EKOS system ) in combination with anticoagulation versus anticoagulation alone , for the treatment of acute , intermediate - high - risk pulmonary embolism . Also presented at VIVA21 late - breaking clinical data from the KNOCOUT PE registry , which reaffirmed the safety and efficacy of the EKOS system for the treatment of patients with intermediate - high and high - risk pulmonary embolism ( PE ) and found zero intracerebral hemorrhages as well as low major bleeding rates among the patients in the analysis . • Presented positive late - breaking clinical trial data for the Eluvia ™ Drug - Eluting Vascular Stent System and the Ranger ™ Drug - Coated Balloon at VIVA21 , with the Eluvia stent exhibiting superiority compared to bare metal stents - the largest randomized trial of drug - eluting therapies in the field of peripheral artery disease - and the Ranger DCB demonstrating continued high rates of primary patency and a significant reduction in reinterventions at two years . • Announced late - breaking results from the EPOCH clinical trial , which demonstrated improved progression - free survival in patients with metastatic colorectal cancer after treatment with TheraSphere ™ Y - 90 Glass Microspheres and represents the first positive phase 3 study for selective internal radiation therapy in any disease setting . Data from the trial was presented at the European Society for Medical Oncology ( ESMO ) Congress 2021 , simultaneously published in the Journal of Clinical Oncology and is expected to support the company's regulatory submission to the FDA for an expanded indication . • Presented at Heart Rhythm 2021 , the Heart Rhythm Society's Annual Meeting , positive real - world data supporting the next - generation WATCHMAN FLX ™ and legacy WATCHMAN ™ Left Atrial Appendage Closure Devices as alternatives to oral anticoagulation therapy for stroke risk reduction in people with non - valvular atrial fibrillation . Findings included patient follow - up visit data from the European FLXibility registry with the WATCHMAN FLX device demonstrating high rates of effective LAA closure and low rates of short - term complications through 120 days . • Received Japanese Pharmaceuticals and Medical Devices Agency ( PMDA ) approval and commenced the Japanese launch of the POLARXTM Cryoablation System , which is indicated for the treatment of patients with paroxysmal atrial fibrillation ( AF ) , an intermittent form of AF which causes an irregular and often abnormally fast heart rate . 1. Operational net sales growth excludes the impact of foreign currency fluctuations . 2. Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales . 3 We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions , healthcare sectors and our global capabilities . Periodically , we assess our list of Emerging Markets countries , and effective January 1 , 2021 , modified our list to include the following countries : Brazil , Chile , China , Colombia , Czech Republic , India , Indonesia , Malaysia , Mexico , Philippines , Poland , Russia , Saudi Arabia , Slovakia , South Africa , South Korea , Taiwan , Thailand , Turkey and Vietnam . We have revised prior period amounts to conform to the current year's presentation which had an immaterial impact on previously reported Emerging Markets net sales . 4. We have three historical reportable segments comprised of Medical Surgical ( MedSurg ) , Rhythm and Neuro , and Cardiovascular , which represent an aggregation of our operating segments that generate revenues from the sale of medical devices ( Medical Devices ) . 5. On March 1 , 2021 , we completed the sale of the Specialty Pharmaceuticals business . Our consolidated net sales include Specialty Pharmaceuticals up to the date of the closing of the transaction . Specialty Pharmaceuticals net sales were substantially U.S. based and presented as a stand - alone operating segment alongside our Medical Device reportable segments . 6. Data on file at Boston Scientific Corporation . Market research is as of 2019 and includes projections for 2020 , incorporating estimates for the COVID - 19 pandemic . Net sales for the third quarter by business and region : Three Months Ended September 30 , ( in millions ) 2021 2020 Reported Basis Endoscopy $ Urology and Pelvic Health 533 384 $ 475 350 12.1 % 9.9 % Increase / ( Decrease ) Less : Impact Less : Impact of of Foreign Currency Fluctuations Operational Basis 0.6 % 0.5 % 11.4 % 9.4 % 2.8 % Recent Acquisitions / Divestitures ― % Organic Basis 11.4 % 6.6 %